The 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) has been grandly held in Phoenix, Arizona, USA, from November 4 to 8, 2026. As one of the world's largest and most prestigious international conferences focused on cancer immunotherapy, the SITC Annual Meeting is dedicated to advancing the science and application of cancer immunotherapy, discovering breakthroughs, and improving the prognosis for cancer patients.

Two studies of Nolgileucel (GC101), the world's first TIL therapy developed by Juncell Therapeutics that does not require high-intensity lymphodepletion chemotherapy or the administration of IL-2, have been selected, with posters presenting its progress in advanced non-small cell lung cancer (NSCLC) and recurrent high-grade glioma (HGG).

A NSCLC patient with KRAS mutation who achieved long-term metabolic complete response after GC101 TIL therapy has been reported, and the safety and preliminary efficacy data of GC101 in the treatment of recurrent high-grade glioma will be presented. This latest breakthrough will be shared with global industry experts in the form of a poster presentation and online session.

Poster Details

• Abstract Number: #488

• Abstract Title: Phase I Trial of GC101 TIL, a Modified Autologous Tumor-Infiltrating Lymphocyte Therapy, in Advanced Non-Small Cell Lung Cancer: Long-Term Metabolic Complete Response in a Patient with KRAS mutation

• Presenting Author: Juan Li

• Research Institution: Chinese PLA General Hospital,Peking University Shougang Hospital

• Presentation Time: Saturday, November 7, 2026

The report described a patient with KRAS mutation who had received two prior lines of therapy, but discontinued due to progression or intolerance. After GC101 TIL therapy, the patient achieved sustained target-lesion complete response (CR) from Day 84. Metabolic CR was achieved as assessed by PET-CT with ongoing response beyond 1.5 years. This is the first case of long-term metabolic CR in refractory NSCLC after GC101 TIL therapy, representing an encouraging outcome and supporting furtherapplication of TIL therapy in PD-1-resistant NSCLC.

Poster Details

• Abstract Number: #334

• Abstract Title: Phase 1 Trial of GC101, an IL‑2‑free Autologous Tumor-Infiltrating Lymphocyte (TIL) Therapy, in Recurrent High-grade Glioma: Safety and Preliminary Efficacy

• Presenting Author: Yanming Chen

• Research Institution: The Second Affiliated Hospital of Soochow University

• Presentation Time: Saturday, November 7, 2026

In HGG, median progression-free survival was 9.4 months,and the ORR was 50%. including a CR in grade 4. In terms of safety profile, no dose-limiting toxicities or serious adverse events were observed. GC101 shows encouraging antitumor activity and a favorable safety profile, providing solid evidence-based medical evidence for TIL therapy in the treatment of glioma.